Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

John Young Biography and Net Worth

Insider of Pfizer

John Young is Group President at Pfizer Inc., and is a member of the Company’s Executive Leadership Team.

Prior to this role, John was the Group President of Pfizer Innovative Health, which included six business units: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines and Consumer Healthcare; each business unit focused on developing innovative medicines and vaccines to make a meaningful difference to patients impacted by diseases with significant unmet need. John was also responsible for these businesses in Emerging Markets focused on increasing access to Pfizer’s innovative medicines to people across developing countries in Latin America, Asia, Africa and the Middle East.

Previously, John was the Group President for Pfizer Essential Health where he oversaw a broad portfolio of more than 600 products with a global reach in 160 countries. A scientist by training, John has more than 30 years of experience with Pfizer and has held a number of senior positions across the organization.

John is a member of the Board of Directors of the Consumer Healthcare Joint Venture with GlaxoSmithKline plc, and also Johnson Controls International (JCI). He serves on the Board of BIO (Biotechnology Innovation Organization) and as a member of the UK Government bioscience working group, the Life Sciences Council.

John holds a BSc in Biological Science from Glasgow University and an MBA from Strathclyde Graduate Business School. He is married with three daughters.

What is John D. Young's net worth?: The estimated net worth of John D. Young is at least $5.00 million as of May 10th, 2016. Mr. Young owns 200,399 shares of Pfizer stock worth more than $4,998,953 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Young may own. Learn More about John D. Young's net worth.
How do I contact John D. Young?: The corporate mailing address for Mr. Young and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on John D. Young's contact information.
Has John D. Young been buying or selling shares of Pfizer?: John D. Young has not been actively trading shares of Pfizer within the last three months. Most recently, John D. Young sold 150,000 shares of the business's stock in a transaction on Thursday, November 11th. The shares were sold at an average price of $50.06, for a transaction totalling $7,509,000.00. Learn More on John D. Young's trading history.
Who are Pfizer's active insiders?: Pfizer's insider roster includes Ronald Blaylock (Director), Albert Bourla (DVM), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Albert D.V.M. (DVM), Frank Damelio (EVP), Frank D'Amelio (CFO & Exec. VP ), Jennifer Damico (SVP), Jennifer Damico (SVP), Scott Gottlieb (Director), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.
Are insiders buying or selling shares of Pfizer?: In the last year, Pfizer insiders bought shares 2 times. They purchased a total of 4,000 shares worth more than $107,650.00. The most recent insider tranaction occured on October, 30th when Director Scott Gottlieb bought 1,000 shares worth more than $28,240.00. Insiders at Pfizer own 0.1% of the company. Learn More about insider trades at Pfizer.
Information on this page was last updated on 10/30/2024.

John D. Young Insider Trading History at Pfizer

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/11/2021	Sell	150,000	$50.06	$7,509,000.00
5/10/2016	Sell	41,700	$33.53	$1,398,201.00	200,399
11/7/2014	Sell	21,600	$29.89	$645,624.00

John D. Young Buying and Selling Activity at Pfizer

Pfizer Company Overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Today's Range

Now: $24.86

$24.86

50 Day Range

MA: $28.36

$24.80

$30.20

2 Week Range

Now: $24.86

$24.48

$31.54

Volume

504,917 shs

Average Volume

38,277,230 shs

Market Capitalization

$140.88 billion

P/E Ratio

33.60

Dividend Yield

6.69%

Beta

0.67

Blackrock’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad